Impact of the presence of heart disease, cardiovascular medications and cardiac events on outcome in COVID-19 by Cabezón Villalba, Gonzalo et al.
Address for correspondence: Dr. J. Alberto San Roman, Department of Cardiology, Institute of Heart Sciences (ICICOR), 
Hospital Clínico Universitario, Valladolid, Spain, e-mail: asanroman@secardiologia.es
Received: 7.10.2020 Accepted: 25.02.2021
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download 
articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
Impact of the presence of heart disease,  
cardiovascular medications and cardiac  
events on outcome in COVID-19
Gonzalo Cabezón Villalba1 , Ignacio J. Amat-Santos1, 2, Carlos Dueñas3,  
Diego López Otero2, 4, Pablo Catalá1, Álvaro Aparisi1, Javier López-Pais2, 4,  
Carla Eugenia Cacho Antonio4, Jordi Candela1, Pablo Antúnez Muiños4,  
José Francisco Gil1, Teba González Ferrero4, Marta Marcos1, Marta Pérez-Poza4,  
Gino Rojas1, Oscar Otero García4, Carlos Veras1, Víctor Jiménez Ramos4,  
Aitor Uribarri1, 2, Ana Revilla1, 2, Pablo Elpidio García-Granja1, 2, Itzíar Gómez1, 2,  
José Ramón González-Juanatey2, 4, J. Alberto San Román1, 2
1Cardiology Department, Hospital Clínico Universitario, Valladolid, Spain 
2Centro de Investigación Biomédica en Red — Cardiovascular (CIBER-CV), Spain 
3Department of Infectious Diseases, Hospital Clínico Universitario, Valladolid, Spain 
4Cardiology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain
Abstract
Background: Cardiovascular risk factors and usage of cardiovascular medication are prevalent 
among coronavirus disease 2019 (COVID-19) patients. Little is known about the cardiovascular im-
plications of COVID-19. The goal herein, was to evaluate the prognostic impact of having heart disease 
(HD) and taking cardiovascular medications in a population diagnosed of COVID-19 who required 
hospitalization. Also, we studied the development of cardiovascular events during hospitalization. 
Methods: Consecutive patients with definitive diagnosis of COVID-19 made by a positive real time-
-polymerase chain reaction of nasopharyngeal swabs who were admitted to the hospital from March 15 
to April 14 were included in a retrospective registry. The association of HD with mortality and with 
mortality or respiratory failure were the primary and secondary objectives, respectively.
Results: A total of 859 patients were included in the present analysis. Cardiovascular risk factors were 
related to death, particularly diabetes mellitus (hazard ratio in the multivariate analysis: 1.810 [1.159–
–2.827], p = 0.009). A total of 113 (13.1%) patients had HD. The presence of HD identified a group of 
patients with higher mortality (35.4% vs. 18.2%, p < 0.001) but HD was not independently related to 
prognosis; renin–angiotensin–aldosterone system inhibitors, calcium channel blockers, diuretics and 
beta-blockers did not worsen prognosis. Statins were independently associated with decreased mortal-
ity (0.551 [0.329–0.921], p = 0.023). Cardiovascular events during hospitalization identified a group 
of patients with poor outcome (mortality 31.8% vs. 19.3% without cardiovascular events, p = 0.007). 
Conclusions: The presence of HD is related to higher mortality. Cardiovascular medications taken 
before admission are not harmful, statins being protective. The development of cardiovascular events 
during the course of the disease is related to poor outcome. (Cardiol J 2021; 28, 3: 360–368)
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On Thursday, December 12th, some people who 
had visited the Huanan Seafood Market were found 
to present viral pneumonia, later labeled by the 
World Health Organization as coronavirus disease 
2019 (COVID-19). Since then, the outbreak which 
has changed our lives forever has infected more 
than 100 million people around the world carrying 
a mortality of approximately 2% [1]. Comorbidi-
ties, which have a clear impact on prognosis, are 
frequent in patients with severe COVID-19 [2–5]. 
Zhou et al. [6] have seen that 86% of patients 
who presented coronary artery disease died. In 
a series of 487 patients, cardiovascular diseases 
were more frequent in patients who died (8.2% vs. 
1.6%) but only age, male gender and hypertension 
independently predicted death [7]. Besides, the 
term “cardiovascular diseases” was not defined. 
Viral infections can contribute to acute coronary 
syndromes both by a direct effect on an atheroscle-
rotic plaque inducing inflammation in the endothe-
lium and smooth muscle cells, or by an indirect effect 
causing a hyperinflammatory stage with elevated 
pro-inflammatory cytokines, which may elicit plaque 
rupture of a coronary artery [8–11]. While some 
investigations have dealt with the impact of myo-
cardial injury [12] or ischemic heart disease [13] 
on the outcome of patients with COVID-19, little is 
known about other types of heart disease (HD) like 
valvular disease or other cardiomyopathies.
The impact of HD and outcome has not been 
studied in other diseases with many similarities to 
COVID-19, the Middle East respiratory syndrome 
and the severe acute respiratory syndrome. Even-
tually, if patients with HD have worse outcomes 
than other patients, public health policies should be 
designed to target those patients as a priority group 
for vaccination against the severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2).
Furthermore, the prognostic consequences 
of taking cardiovascular medications are undeter-
mined. While some authors warn about the harmful 
effect of renin–angiotensin–aldosterone system 
(RAAS) blockers and advise its discontinuation to 
prevent poor outcome [14] others advocate main-
taining these drugs until more evidence is available 
[15]. There is little information concerning statins.
In addition, cardiovascular events could occur 
during the course of the disease, such as myocardial 
infarction, decompensated heart failure, myocardi-
tis and others. Nonetheless, the rate, and impact 
on outcome of different cardiovascular events are 
far from clear.
Keeping in mind this background, we have 
assessed the cardiovascular implications of 
COVID-19. Thus, the present study investigated 
the prognostic impact of having HD and taking 
cardiovascular medications in a well characterized 
population diagnosed of COVID-19 who required 
hospitalization. In addition, the development of 
cardiovascular events during hospitalization was 
also studied. 
Methods
This is an observational and retrospective 
multicenter study with a total of 210 variables per 
patient gathered in a specific database from data 
prospectively collected from the electronic medi-
cal records. All consecutive non-selected patients 
with definitive diagnosis of COVID-19 made by 
a positive real time-polymerase chain reaction of 
nasopharyngeal swabs who were admitted to two 
tertiary hospitals from March 15 to April 14 were 
included. No exclusion criteria were considered. 
Follow-up after discharge from hospital was not 
performed. 
A descriptive analysis of heart related charac-
teristics of a COVID-19 population was carried out. 
Association of HD with mortality and the composite 
of mortality or respiratory failure were the primary 
and secondary objectives, respectively.
Data recorded at admission covered epide-
miological, clinical, laboratory (complete blood 
count, coagulation testing including D-dimer, iron 
metabolism including ferritin, electrolytes, as-
sessment of liver and renal function, C-reactive 
protein, erythrocyte sedimentation rate, lactate 
dehydrogenase, procalcitonin and creatine kinase), 
electrocardiogram (ECG) when available, and 
chest-X ray parameters. Computed tomography 
scan was performed when indicated by the physi-
cian in charge of the patient. Interpretation of chest 
imaging tests were performed by an expert radi-
ologist. Troponin and interleukin-6 were obtained 
at the discretion of the physician. The study was 
approved by the local ethics committee.
Definitions
Ischemic heart disease comprised patients 
with a previous diagnostic angiography, previous 
myocardial infarction and patients with no anatomi-
cal confirmation but symptoms compatible and, at 
least, one noninvasive positive test for ischemia. 
Valvular heart disease was diagnosed when the pa-
tient had moderate or severe dysfunction of at least 
one valve. Cardiovascular events were defined as 
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follows: heart failure, pericarditis and myocardi-
tis were defined according to the corresponding 
guidelines of the European Society of Cardiology 
[16–18]; acute myocardial infarction was diagnosed 
when the patient presented compatible chest pain, 
ST changes and elevation of troponin. Isolated el-
evation of troponin was considered as myocardial 
injury but not as an infarction. Atrial fibrillation 
was regarded as an event when it appeared during 
hospitalization. Respiratory failure was defined as 
pO2 < 60 mmHg or SatO2 < 90% without oxygen 
support at any moment of the patient’s hospital-
ization. Azithromycin, hydroxychloroquine and 
lopinavir-ritonavir were considered drugs that may 
cause QT interval prolongation.
Statistical analysis
Categorical variables were reported as abso-
lute values and percentages. Continuous variables 
were reported as the mean ± standard deviation or 
median and interquartile range. Normal distribu-
tion of quantitative variables were verified with the 
Kolmogorov-Smirnov test. Categorical variables 
were compared with the c2 test and the Fisher exact 
test. Continuous variables were compared with the 
Student t test or its equivalent for nonparametric 
tests, the Mann-Whitney U test was used for vari-
ables that were not normally distributed.
To identify factors that were predictive of 
mortality and the composite endpoint (mortality 
or respiratory failure), a logistic regression model 
with the maximum likelihood method was con-
structed by using backward stepwise selection, 
which included the variables that were statistically 
significant in the univariate analysis. No more than 
1 variable per 10 outcome events was entered in 
the logistic model to avoid overfitting. For the final 
model we calculated odds ratios adjusted for each 
of the variables included, along with their 95% 
confidence intervals. Goodness of fit for each model 
was determined with the Hosmer-Lemeshow test 
and C-index.
All data were entered into a database and ana-
lyzed with version 15.0 of the Statistical Package 
for Social Sciences (SPSS Inc., Chicago, IL). Dif-
ferences were considered statistically significant 
when p was < 0.05.
Results
Characteristics of the patients
A total of 859 patients made up the present 
study group. Main characteristics of patients are 
shown in Table 1. Mean age was 68 years and 
49.5% were female (n = 425). Among comorbid 
conditions, 49.5% presented arterial hypertension, 
19.3% diabetes mellitus, 40.5% dyslipidemia, 9.3% 
chronic obstructive pulmonary disease (COPD) 
and 6.9% chronic kidney disease (CKD). A total 
of 20.5% patients died (n = 176). 
Heart disease was present in 113 (13.1%) pa-
tients (Table 2). The most frequent was ischemic 
HD with 71 patients; 34 patients had valvular HD 
and 14 cardiomyopathy; 6 patients presented more 
than one.
Comparison of patients with and without HD
Patients with HD were older and presented 
higher rates of arterial hypertension, diabetes mel-
litus, dyslipidemia and CKD as shown in Table 1. 
Regarding laboratory data, HD patients had more 
lymphopenia, anemia, higher values of creatinine, 
D-dimer and procalcitonin. Sinus rhythm was more 
frequent in patients without HD. Patients with HD 
suffered more respiratory failure and death.
Predictors of outcome
Multivariate analysis for predictors of death 
was performed, included  in the model were all vari-
ables that were significant in the univariate analy-
sis, namely: age, hypertension, diabetes mellitus, 
CKD, presence of HD, COPD, dyslipidemia, lym-
phocyte count < 1000/mm3, D-dimer > 500 mg/L, 
C-reactive protein (CRP) > 10 mg/mL and hemo-
globin < 10 mg/dL. As can be seen in Table 3, 
age, diabetes mellitus, COPD, lymphocyte count 
< 1000/mm3 and CRP > 10 mg/L were indepen-
dently associated with mortality. HD was strongly 
associated with mortality, but was not an independ-
ent predictor of death.
For the composite endpoint (respiratory failure 
and death), variables predictive in the univariate 
analysis were age, hypertension, diabetes mellitus, 
CKD, presence of HD, lymphocyte count < 1000/ 
/mm3, D-dimer > 500 mg/L, CRP > 10 mg/mL and 
hemoglobin < 10 mg/dL. Independent predictors of 
the composite endpoint after multivariate analysis 
were age, diabetes mellitus, CKD, low lymphocyte 
count, high D-dimer, high CRP. Again, HD was not 
independently related to the composite endpoint.
Medications at admission and mortality
Table 4 shows the mortality rate of patients 
according to the medications taken at admission. 
Univariate and multivariate analysis of composite 
endpoint according to medication are depicted in 
Table 5. Angiotensin converting enzyme (ACE) 
inhibitors, angiotensin receptor blockers and 
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beta-blockers were not independent predictors 
of death. However, statins were independently 
associated to better prognosis after multivariate 
analysis.
Clinical course
During hospitalization 85 patients developed 
cardiovascular events (Table 6), 24 of them (28.2%) 
had history of HD. The development of cardio-
Table 1. Main characteristics of the overall population and comparison between patients with heart 








Mean age 68.1 75.6 67.0 < 0.001
Female 425 (49.5%) 50 (44.2%) 375 (50.2%) 0.233
Comorbidities
Hypertension 425 (49.5%) 86 (76.1%) 339 (45.4%) < 0.001
Diabetes mellitus 166 (19.3%) 43 (38.1%) 123 (16.5%) < 0.001
Chronic kidney disease 59 (6.9%) 16 (14.2%) 43 (5.8%) < 0.001
Dyslipidemia 348 (40.5%) 79 (69.9%) 269 (36.1%) < 0.001
Current smoker 36 (4.2%) 3 (2.7%) 33 (4.4%) 0.612
Chronic obstructive pulmonary disease 79 (9.3%) 15 (13.3%) 64 (8.7%) 0.120
Clinical picture 
Temperature > 37.5o 627 (73.0%) 81 (71.7%) 546 (73.2%) 0.753
Cough 581 (67.6%) 61 (54.0%) 520 (69.7%) 0.001
Dyspnea 402 (46.8%) 55 (48.7%) 347 (46.5%) 0.668
Diarrhea 182 (21.2%) 22 (19.5%) 160 (21.4%) 0.631
Blood analysis
Leukocytes > 10.000/mm3 136 (15.9%) 24 (21.6%) 112 (15.0%) 0.076
Leukocytes < 4.000/mm3 137 (16.0%) 21 (18.9%) 116 (15.6%) 0.368
Lymphocytes < 1.000/mm3 478 (55.6%) 76 (67.0%) 402 (53.9%) 0.010
Hemoglobin < 10 g/dL 52 (6.1%) 15 (13.4%) 37 (5.0%) 0.001
Platelets < 150.000/mm3 210 (24.5%) 35 (31.2%) 175 (23.5%) 0.076
Aspartate aminotransferase > 40 U/L 356 (41.4%) 53 (46.9%) 303 (40.5%) 0.230
Alanine aminotransferase > 40 U/L 311 (36.2%)  41 (36.1%) 270 (36.2%) 0.991
Lactate dehydrogenase > 250 U/L 564 (65.7%) 78 (69.4%) 486 (65.2%) 0.415
D-dimer > 500 µg/L 620 (72.2%) 92 (81.1%) 528 (70.8%) 0.027
Creatinine > 1.5 mg/dL 119 (13.9%) 31 (27.7%) 88 (11.8%) < 0.001
C-reactive protein > 10 mg/L 618 (71.9%) 83 (73.4%) 535 (71.7%) 0.711
Procalcitonin > 0.5 ng/mL 126 (14.7%) 26 (22.8%) 100 (13.6%) 0.019
Chest-X ray 
Abnormal 799 (93.0%) 104 (92.0%) 695(93.2%) 0.664
Local opacity/shadowing 421 (40.9%) 42 (37.6%) 379 (41.4%) 0.472
Diffuse/bilateral shadowing/opacity 559 (65.1%) 76 (67.0%) 483 (64.9%) 0.671
Interstitial pattern 140 (16.3%) 19 (17.2%) 121 (16.1%) 0.793
Alveolointerstitial pattern 367 (42.7%) 46 (40.6%) 321 (43.0%) 0.651
Electrocardiogram
Sinus rhythm 760 (88.5%) 83 (73.3%) 677 (90.6%) < 0.001
Clinical evolution
In-hospital death 176 (20.5%) 40 (35.4%) 136 (18.2%) < 0.001
Respiratory failure 350 (40.8%) 64 (56.4%) 286 (38.5%) < 0.001
Mechanical ventilation 73 (8.5%) 8 (7.1%) 65 (8.7%) 0.562
Heart failure 67 (7.8%) 19 (16.8%) 48 (6.4%) 0.001
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vascular events during hospitalization identified 
a group of patients with poor outcome (mortality 
31.8% vs. 19.3% in patients without cardiovascular 
events, p = 0.007). Acute heart failure was the 
most frequent cardiovascular event (n = 64) and 
was associated with increased mortality (32.8% vs. 
16.6%, p > 0.001).
Table 2. Characterization of the 113 patients with 
heart disease.
Condition N Mortality
Ischemic heart disease 71 (63%) 25 (35.2%)
Previous myocardial infarction 49 17 (34.7%)
Percutaneous revascularization: 56 20 (35.7%)
One vessel 35 13 (37.1%)
Two vessels 13 4 (30.8%)
Three vessels 8 3 (37.5%)
Left anterior descending artery 36 13 (36.1%)
Surgical revascularization 4 0 (0%)
Valvular heart disease 34 (30%) 14 (41%)
Mitral regurgitation 11 5 (45%)
Mitral stenosis 0 —
Aortic regurgitation 5 1 (20%)
Aortic stenosis 12 6 (50%)
Prosthesis 5 1 (20%)
Other 5 1 (20%)
Cardiomyopathy 14 (12%) 6 (43%)
Dilated 10 4 (40%)
Hypertrophic 4 2 (50%)
Table 3. Predictors of mortality and the composite endpoint.
Variable Univariate Multivariate
OR (95% CI) P OR (95% CI) P
Mortality
Age 1.093 (1.074–1.111) < 0.001 1.076 (1.057–1.095) < 0.001
Hypertension 2.928 (2.052–4.179) < 0.001
Diabetes mellitus 2.715 (1.866–3.949) < 0.001 1.810 (1.159–2.827) 0.009
Chronic kidney disease 4.294 (2.500–7.375) < 0.001 1.882 (0.984–3.601) 0.056
Heart disease 2.458 (1.602–3.771) < 0.001
COPD 2.296 (1.402–3.759) 0.001 1.787 (1.004–3.182) 0.048
Dyslipidemia 1.675 (1.200–2.338) 0.002
Lymphocytes < 1000/m3 2.350 (1.638–3.371) < 0.001 1.692 (1.111–2.577) 0.014
D-dimer > 500 mg/L 2.388 (1.522–3.747) < 0.001
C-reactive protein > 10 mg/L 3.383 (2.083–5.492) < 0.001 2.786 (1.639–4.734) < 0.001
Hemoglobin < 10 g/dL 4.000 (2.257–7.089) < 0.001
Mortality + respiratory failure
Age 1.045 (1.034–1.056) < 0.001 1.029 (1.017–1.041) < 0.001
Hypertension 2.047 (1.556–2.692) < 0.001
Diabetes mellitus 2.664 (1.877–3.782) < 0.001 2.173 (1.459–3.236) < 0.001
Chronic kidney disease 4.114 (2.252–7.515) < 0.001 2.617 (1.331–5.144) 0.005
Heart disease 2.230 (1.487–3.344) < 0.001
Lymphocytes < 1000/m3 2.534 (1.911–3.361) < 0.001 2.074 (1.509–2.849) < 0.001
D-dimer > 500 mg/L 2.191 (1.582–3.035) < 0.001 1.523 (1.061–2.186) 0.023
C-reactive protein > 10 mg/L 3.434 (2.445–4.824) < 0.001 3.160 (2.189–4.559) < 0.001
Hemoglobin < 10 g/dL 3.357 (1.813–6.216) < 0.001
CI — confidence interval; COPD — chronic obstructive pulmonary disease; OR — odds ratio
Table 4. Crude mortality rate according to the 
medications taken at admission
N Mortality
Angiotensin converting  
enzyme inhibitors
147 36 (24.5%) 
Angiotensin receptor blockers 176 49 (27.8%)
Beta-blockers 158 57 (36.1%)
Calcium antagonists 82 28 (34.1%)
Diuretics 130 51 (39.2%)
Statins 295 66 (22.4%)
Acetylsalicylic acid 131 43 (32.8%)
Antivitamin K 94 42 (44.7%)
Direct oral anticoagulants 31 18 (58.1%)
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Electrocardiogram 
Electrocardiogram was performed in 485 
(57.9%) patients. Only 50.8% of patients admit-
ted in March had an ECG available (308 of 606) 
but this percentage rose to 65.8% (166 of 252) in 
April. In patients with ECG performed QTc was 
measured in 52.8% (n = 256) and QT interval 
lengthening (longer than 440 ms in men and 460 ms 
in women) was found in 16 (6.3%) patients. Of 
the 353 patients without ECG, 326 (92.3%) took, 
at least, one medication which lengthens the QT 
interval and 304 (86.1%) at least two.
Discussion
This study regarding hospitalized patients 
with COVID-19 had the goal to examine specific 
cardiovascular aspects, and several findings have 
to be underlined: 1) cardiovascular risk factors are 
common in COVID-19 and entail poor prognosis, 
particularly diabetes mellitus; 2) the presence of HD 
identifies a group of patients with poor outcome; HD 
is not independently related to prognosis, though; 
3) cardiovascular medications normally used are not 
harmful, and statins may be protective; 4) cardiovas-
cular events are frequent and negatively impact on 
prognosis. All these assertions not only emphasize 
the close relationship between COVID-19 and the 
heart but also highlight the importance of cardiolo-
gists being part of the multidisciplinary team taking 
care of these patients.
Cardiovascular risk factors are frequent in 
COVID-19 patients. Diabetes mellitus is as fre-
quent as 20% [12], hypertension 30% [4] and active 
smoking 12.6% [3]. Surprisingly, dyslipidemia was 
not reported in any of the series. In the current 
cohort, the prevalence of these risk factors is even 
greater. Importantly, diabetes mellitus was a very 
powerful predictor of death in the current series, 
in line with previous publications [19].
Several physiopathologic mechanisms have 
been proposed to explain the poor prognosis in dia-
Table 5. Univariate and multivariate analysis of mortality according to medication. 
Variable Univariate Multivariate
OR (95% CI) P OR (95% CI) P
Age 1.093 (1.074–1.111) < 0.001 1.079 (1.060–1.099) < 0.001
Hypertension 2.928 (2.052–4.179) < 0.001
Diabetes mellitus 2.715 (1.866–3.949) < 0.001 1.886 (1.181–3.012) 0.008
Chronic kidney disease 4.294 (2.500–7.375) < 0.001
Heart disease 2.458 (1.602–3.771) < 0.001
COPD 2.296 (1.402–3.759) 0.001 1.817 (1.005–3.287) 0.048
Dyslipidemia 1.675 (1.200–2.338) 0.002 1.651 (0.996–2.736) 0.052
Lymphocytes < 1000/m3 2.350 (1.638–3.371) < 0.001 1.668 (1.088–2.526) 0.019
D-dimer > 500 mg/L 2.388 (1.522–3.747) < 0.001
C-reactive protein > 10 mg/L 3.383 (2.083–5.492) < 0.001 2.741 (1.610–4.666) < 0.001
Hemoglobin < 10 g/dL 4.000 (2.257–7.089) < 0.001 2.376 (1.145–4.931) 0.020
ACE inhibitor 1.325 (0.871–2.016) < 0.188
Angiotensin receptor blocker 1.691 (1.154–2.480) 0.007
Beta-blockers 2.750 (1.880–4.023) < 0.001
Statins 1.156 (0.816–1.628) 0.419 0.551 (0.329–0.921) 0.023
ACE — angiotensin convertin enzyme; CI — confidence interval; COPD — chronic obstructive pulmonary disease; OR — odds ratio
Table 6. Cardiovascular events during hospital 
stay. Several patients had more than one event. 
Cardiovascular event N (%) Mortality
Heart failure 64 (7.4%) 21 (33%) 
Acute myocardial  
infarction
4 (0.4%) 0 (0%) 
Pericarditis 3 (0.3%) 1 (33%) 
Myocarditis 2 (0.2%) 1 (50%) 
Atrial fibrillation 12 (1.4%) 3 (25%) 
Ventricular tachycardia 
or sudden cardiac death
1 (0.1%) 1 (100%) 
Other cardiovascular 
events
4 (0.4%) 1 (25%) 
TOTAL 90 (10.5%)
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betic patients with COVID-19, linked to increased 
ACE2, furin and interleukin-6 levels [20, 21].
There are multiple mechanisms proposed 
to explain the association between HD and poor 
outcome in COVID-19. Patients in the present 
study with HD show more anemia, higher levels of 
D-dimer and procalcitonin and worse renal function, 
which suggests that the worse clinical evolution of 
these patients may be related to an aggressive 
hyperinflammatory and prothrombotic response 
and to a deficient immune response as suggested 
by the lower levels of lymphocytes.
Despite HD, it did not constitute an independ-
ent predictor of death in the population study, 
the current work shows that the presence of HD 
identifies a high-risk population and is a marker of 
poor outcome in COVID-19. Therefore, intensive 
surveillance and precocious treatment could be 
beneficial in this population. Public health policies 
should target those patients as a priority group for 
the vaccination against the SARS-CoV-2.
Discontinuing cardiovascular medications 
taken at admission during COVID-19 has been 
a controversial topic. Increased ACE2 receptor ex-
pression with RAAS blockade has been document-
ed, which theoretically would favor SARS-CoV-2 
entry into the cells. Nonetheless, other animal 
[22] and human studies [23] could not reproduce 
this upregulation of the receptor during treatment 
with RAAS blockade. Some authors warn about 
the harmful effect of RAAS blockers and advise its 
discontinuation to prevent poor outcome [14] while 
others claim to maintain these drugs until more 
evidence is available [15, 24]. The present data 
show that RAAS blockers are not harmful as seen 
in a recent Spanish study [25]. Only a prospective 
randomized study in patients free of the infection 
would provide evidence-based answers, which 
seems very difficult to undertake. In this regard, 
the investigators of the RASTAVI trial, which is 
currently randomizing patients with severe aortic 
stenosis who have indication for a percutaneous 
aortic prosthesis to ramipril or not, have shown 
that randomization to ramipril had no impact in the 
incidence or severity of COVID-19 [26].
Beta-blockers and statins are widely used due 
to their multiple beneficial effects in cardiovas-
cular disease. In particular, statins may improve 
endothelial dysfunction, decrease expression of 
pro-inflammatory cytokines like interleukin-6 
[27] and modulate the immune response at dif-
ferent levels, including immune cell adhesion 
and migration, antigen presentation, and cytokine 
production [28]. 
The current study results suggest that keep-
ing cardiovascular related medication during 
COVID-19 is not harmful. Indeed, statins were 
found to be protective, which could be related to 
their pleiotropic effects. It has to be emphasized 
that this refers to medications the patient is already 
taking at admission and the present results do not 
support initiating these medications during hospital 
stays to enhance outcome.
Acute heart failure may be present in 23% of pa-
tients in their initial presentation for COVID-19 [6]. 
In the current cohort, acute heart failure was the 
most frequent cardiovascular event and showed 
a significant association with mortality. Results con-
firm the suspicions raised by previous works [29, 30]. 
Bearing this in mind, we recommend an active search 
of heart failure for its prompt diagnosis and treatment 
during COVID-19. However, we are aware of the 
difficulty of making a differential diagnosis between 
heart failure and respiratory failure in this setting.
There is available evidence of the occur-
rence of myocarditis secondary to SARS-CoV-2, 
confirmed by magnetic resonance and autopsy 
findings of inflammatory mononuclear infiltrate 
in myocardial tissue [31]. In the present cohort 
2 cases of myocarditis were diagnosed and both 
required venoarterial extracorporeal membrane 
oxygenation as life support therapy.
With respect to acute coronary syndromes, it 
has been previously demonstrated the increased 
incidence in other viral infections like influenza 
[10, 32]. Frequency of type I myocardial infarction 
of patients with COVID-19 is unknown. The true 
prevalence in this setting may be underreported 
given the logistical challenges associated with lim-
ited testing and cardiac catheterization laboratory 
availability in this scenario.
Another concern about the management of 
COVID-19 is to reduce as much as possible the 
incidence of life-threatening ventricular tachyar-
rhythmias. COVID-19 treatment includes the use 
of hydroxychloroquine and azithromycin, which 
have known potential to induce QT prolongation. 
Besides, lopinavir-ritonavir presents a possible 
“torsade de pointes” risk. 
Despite the importance of ECG to detect 
lengthening of QT interval it was performed in 
only 56.7% of the cohort. Physicians taking care of 
COVID-19 patients may be unaware of arrhythmo-
genic capacity of commonly used medications in 
this disease, particularly if used in combination. 
As stated previously, it was herein considered that 
hydroxychloroquine, azithromycin and lopinavir-
-ritonavir prolongers of the QT interval. 
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Limitations of the study
Some limitations have to be recognized. The 
protocol did not include troponin and B-type natri-
uretic peptide measurements that were done at the 
physicians’ discretion, and a putative link between 
these parameters and the development of cardiac 
complications was not explored. Being the number 
of patients without ECG a limitation, it reflects 
the real-life practice in busy hospitals struggling 
with a massive admission of patients but having 
limited capacity and resources. The conclusions 
made here cannot be extrapolated to outpatients 
given that only patients admitted to the hospital 
were included. Finally, although the utmost care 
was taken to accurately apply our database, unin-
tended mistakes cannot be ruled out. Nonetheless, 
to verify reliability of the gathered data 50 patient 
records were reviewed by an independent observer 
and only 0.04% variables were found to be incor-
rect. Moreover, all quantitative outliers (more than 
mean ± 2 standard deviation) were checked by an 
independent observer. 
Conclusions
Heart disease identifies patients with higher 
mortality, but it is not an independent predictor of 
death. Cardiovascular medications taken before 
admission are not harmful, statins being protec-
tive. The development of cardiovascular events is 
related to poor outcome.
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